Laurus Labs Limited (BOM:540222)

India flag India · Delayed Price · Currency is INR
650.45
-1.20 (-0.18%)
At close: Apr 23, 2025
50.22%
Market Cap 348.09B
Revenue (ttm) 56.29B
Net Income (ttm) 3.58B
Shares Out n/a
EPS (ttm) 6.64
PE Ratio 97.14
Forward PE n/a
Dividend 0.80 (0.12%)
Ex-Dividend Date Nov 6, 2024
Volume 65,374
Average Volume 93,649
Open 658.90
Previous Close 651.65
Day's Range 642.60 - 659.95
52-Week Range 386.85 - 657.45
Beta n/a
RSI 62.20
Earnings Date Apr 25, 2025

About Laurus Labs

Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides oral solid formulations for ARVs, anti-diabetic, cardiovascular, and PPIs. In addition, the company offers contract development and manufacturing organizational ser... [Read more]

Industry Medicinal Chemicals and Botanical Products
Founded 2005
Employees 6,007
Stock Exchange Bombay Stock Exchange
Ticker Symbol 540222
Full Company Profile

Financial Performance

In 2023, Laurus Labs's revenue was 50.41 billion, a decrease of -16.55% compared to the previous year's 60.41 billion. Earnings were 1.61 billion, a decrease of -79.68%.

Financial Statements

News

There is no news available yet.